Indian pharma stocks fall after Trump's new drug tariffs

Indian pharmaceutical stocks fell 2.6% on Friday after U.S. President Donald Trump announced a 100% tariff on branded and patented drugs, effective October 1. While the U.S. accounts for over a third of India's drug exports, primarily cheaper generics valued at $10.5 billion in fiscal 2025, analysts suggest the near-term impact may be limited. However, uncertainty remains regarding potential future tariffs on complex generics and biosimilars, posing a risk to the sector.

Analysis

The Indian pharmaceutical sector faced a sharp, broad-based sell-off, with the .NIPHARM index declining 2.6% and all its constituents trading lower following the U.S. announcement of a 100% tariff on branded and patented drugs. While the U.S. is a critical market, absorbing over a third of India's drug exports—a figure that grew 20% to $10.5 billion in fiscal 2025—the immediate impact of this specific tariff is projected to be limited. This assessment, supported by ICICI Securities, is based on the fact that India's exports are predominantly generics, which fall outside the scope of the current tariff. The market's negative reaction, including a 3.4% drop in heavyweight Sun Pharmaceutical, therefore appears to be driven by sentiment and future uncertainty rather than immediate earnings erosion. The key risk highlighted by analysts is the potential for the U.S. to expand this tariff embargo to include complex generics and biosimilars, which creates a significant overhang on the sector's future growth trajectory.

Key Decisions for Investors

• The market's 2.6% drop may represent an overreaction given the tariffs target branded drugs, not the generics that form the bulk of Indian exports, so investors should assess whether the sell-off presents a tactical opportunity.
• The primary risk to monitor is any change in U.S. trade policy that expands tariffs to complex generics and biosimilars, which would fundamentally alter the sector's risk profile.
• It is now critical to differentiate within portfolios between Indian pharma companies based on their exposure to patented drugs versus a pure-play generic business model, as their vulnerability to this trade risk is not uniform.